Therapies & Conditions: Berinert is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and adolescent patients.
Administration: Typically administered at a dose of 20 International Units (IU) per kg body weight by intravenous injection. Doses lower than 20 IU/kg body weight should not be administered.
Method: Intravenous use only. Do NOT administer orally.
Side Effects: In clinical studies, the most common adverse reaction reported among subjects who received Berinert in the placebo-controlled clinical trial was dysgeusia (bad taste in mouth).
To report suspected adverse reactions, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or to the FDA at 1-800- FDA-1088 or www.fda.gov/medwatch.
For more detailed information on Berinert, please visit FDA.gov
Frequently Asked Questions
- What is infusion therapy?
Infusion therapy involves the administration of medication through a needle or catheter. It is usually prescribed when a patient’s condition cannot be treated with oral medication. Read more about infusion therapy treatments.
- Is home infusion therapy safe?
Home and alternate site infusion therapy is a proven, safe and effective alternative to hospital inpatient care.[*]Bhole, M. V., Burton, J., & Chapel, H. M. (2008). Self-infusion programmes for immunoglobulin replacement at home: Feasibility, safety and efficacy. Immunology and Allergy Clinics of North America,28(4), 821-832. [*]Souayah, N., Hasan, A., Khan, H., et al. (2011). The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders.Journal of Clinical Neuromuscular Disease, 12(suppl 4), S1-10. For most people, receiving treatment at home or in an alternate treatment setting, like an infusion suite, is preferable to hospital inpatient care. It can provide comfort and convenience for patients and offers less interruption to their daily activities. It can also be a cost-effective alternative to expensive hospital stays.[*]Home infusion therapy: Differences between Medicare and private insurers’ coverage. (2010, June). United States Government Accountability Office Report to Congressional Requesters. Accessed July 23, 2012: http://www.gao.gov/assets/310/305261.pdf. [*]Einodshofer, M. (2012). A plan for medical specialty medications – increase member access, affordability and outcomes while decreasing plan costs. Presented at: 2012 Pharmacy Benefit Management Institute Annual Drug Benefit Conference; 2012 Feb. 22-24; Scottsdale, Ariz.
- What is Option Care Health doing to keep patients and employees safe during the coronavirus outbreak?
As the nation’s largest infusion provider, we are uniquely positioned to treat patients in the safe environment of their own homes and our alternate infusion suites (AIS). We’ve set up a web page that’s regularly updated with the current news regarding COVID-19. Be sure to check back for updates as we continue monitoring this dynamic situation.